Bremelanotide investigated as a centrally acting therapy for Hypoactive Sexual Desire Disorder in women.
Background
The female sexual response is a complex interplay of somatic, psychosocial, and neurobiological factors. Dysfunction in these areas can lead to conditions like hypoactive sexual desire disorder (HSDD), the most common female sexual dysfunction. A recent US study found that 7.4% of women suffer from HSDD, characterized by decreased sexual desire, lack of motivation for sexual activity, and significant patient distress. Despite its prevalence, HSDD is often underdiagnosed, partly due to a historical lack of FDA-approved therapies. Current research suggests HSDD arises from an imbalance between excitatory (norepinephrine, dopamine, oxytocin, melanocortins) and inhibitory (serotonin, opioids, endocannabinoids) neurobiological pathways that regulate sexual response. This review examines emerging treatments targeting these central mechanisms.
Study Design
This article is a review of the current understanding of the female sexual response, the neurobiological basis of hypoactive sexual desire disorder (HSDD), and the landscape of approved and investigational treatments. It synthesizes findings from existing research to describe the models of sexual response and the key excitatory and inhibitory neuromodulator pathways involved. The paper discusses various therapeutic agents, including hormone therapies and centrally acting drugs like flibanserin (Addyi™), buspirone, bupropion, and the melanocortin agonist bremelanotide, in the context of their mechanism of action for treating HSDD in women.
Results
The review identifies an imbalance of central neurobiological pathways as a key potential cause of HSDD. It suggests that hyperactive top-down inhibition from the prefrontal cortex or hypoactive bottom-up excitation to the limbic system may be responsible. Key excitatory neuromodulators cited are norepinephrine, dopamine, oxytocin, and melanocortins. Conversely, serotonin, opioids, and endocannabinoids are identified as key inhibitory neuromodulators. The first FDA-approved drug for premenopausal women with acquired, generalized HSDD, flibanserin, targets these central pathways. Other centrally acting agents under investigation, such as buspirone, bupropion, and bremelanotide, also aim to correct this neurochemical imbalance by modulating players within these excitatory and inhibitory systems.
A recent in-person diagnostic interview study in the USA found that an estimated 7.4% of US women suffer from HSDD, highlighting the significant prevalence of the disorder.
Key Findings
- Hypoactive Sexual Desire Disorder (HSDD) affects an estimated 7.4% of US women.
- HSDD may arise from an imbalance between excitatory (norepinephrine, dopamine, oxytocin, melanocortins) and inhibitory (serotonin, opioids, endocannabinoids) neurobiological pathways.
- Bremelanotide is a centrally acting drug under investigation for HSDD that targets these key neuromodulator pathways.
- The first FDA-approved treatment for HSDD in premenopausal women is flibanserin (Addyi™).
- A primary reason for physicians not diagnosing HSDD was the prior lack of safe and effective FDA-approved therapies.
Why It Matters
This review consolidates the neurobiological framework for understanding HSDD, shifting the focus from purely psychological or hormonal models to a central nervous system-based approach. For clinicians and patients, this reframing supports the use of centrally acting agents like bremelanotide as a valid therapeutic strategy. It underscores that low desire can have a tangible neurochemical basis, which may help destigmatize the condition and encourage more women to seek diagnosis and treatment. The key takeaway is that future treatment protocols for HSDD will increasingly involve drugs that modulate specific neurotransmitter systems, like the melanocortin pathway, to restore a healthy balance between sexual excitation and inhibition. This provides a clear rationale for why peptides and other neuromodulators are at the forefront of pharmaceutical development for female sexual dysfunction.
TitrateLab articles covering PT-141
Written by TitrateLab, separately from the study summarized above.
pt-141
bremelanotide
hsdd
hypoactive sexual desire disorder
female sexual dysfunction
review
